ALCLS Cellectis SA

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market.

The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company’s fourth quarter and full year 2025 results and an update on business activities. Details for the call are as follows:

Dial in information:

Domestic:

International:

Conference ID: CLLSFY

Webcast Link:

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.

Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on and .  

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, 

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, 

Attachment



EN
12/03/2026

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Result...

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on F...

15h / 5m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis publiera ses résultats financiers du quatrième trimestre et ...

Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026 NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer des thérapies innovantes pour le traitement de maladies graves, publiera ses résultats financiers pour le quatrième trimestre et l’exercice 2025 clos au 31 décembre 2025, le jeudi 19 mars 2026 après la clôture du marché aux États-Unis. Une conférence téléphonique se tiendra...

15h / 5m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, March 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights02/28/2026100,590,994105,825,561 For further information on Cellectis, please contact:          Media contacts:              Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,   Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93          Inve...

March 4, 2026 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 mars 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote28/02/2026100 590 994105 825 561 Pour de plus amples informations sur Cellectis, veuillez contacter :       Contacts média :              Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navar...

March 4, 2026 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/01/2026100 590 994105 825 481 Pour de plus amples informations sur Cellectis, veuillez contacter : Contacts média : Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of...

February 4, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch